eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
10/2002
vol. 6
 
Share:
Share:
more
 
 
abstract:

Mechanisms of metastatic bone disease - target for modern treatment

Cezary Szczylik, Wojciech Z. Pawlak

Współcz Onkol (2002), vol. 6, 10, 644-652
Online publish date: 2003/03/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Bone is the third most common organ subject to by cancer metastases. Breast, prostate, lung and renal cancers metastasize to the bone most frequently. The results of metastatic bone disease treatment are better in comparison to metastases developed in other organs. It is possible by dint of understanding the molecular and cellular mechanisms specially involved in metastases to the bones. The initial stages of metastases formation are similar in tumors with different localization. However, bone invasion is dependent on the imbalance between osteoblast and osteoclast function. Direct destruction of bone by cancer cells is not very important. Activated osteoclasts play a pivotal role in both osteolytic, and initial steps of osteoblasic metastases. There are several most important factors involved in the osteoclast activation in-patients with neoplasia: parathyroid hormone-related protein (PTHrP), interleukin-1 (IL-1), interleukin-6 (IL-6), receptor activator of NF-kappaB ligand (RANKL), and macrophage inflammatory protein-1-alpha (MIP-1a). RANKL activity can be blocked by osteoprotegerin (OPG), its soluble decoy receptor. Several positive feedbacks are made in developed bone metastases: cancer cells secrete osteoclast-activating factors that induce bone resorption, while increased bone resorption releases growth factors enhancing tumor growth. The disruption of this "vicious cycle" is the condition of successful treatment of patients with the metastatic bone disease. Bisphosphonates are the first drugs, which specifically block cellular signaling mechanisms involved in the cancer-induced bone disease.
keywords:

cancer, metastatic bone disease, molecular mechanisms, treatment, bisphosphonates

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe